Evaluation of the anti‐aging effects of Zinc‐α2‐glycoprotein peptide in clinical and in vitro study

Abstract

AbstractBackgroundSkin aging, characterized by the deterioration of skin density and elasticity, is a common concern among individuals seeking to maintain a youthful appearance. Zinc‐α2‐glycoprotein (ZAG) is secreted by various body fluids, and is associated with lipolysis and identified as an atopic dermatitis biomarker. This study evaluated the potential of ZAG peptides, which exert multiple benefits such as anti‐aging.Materials and MethodsWe conducted a 4‐week clinical trial on patients with noticeable periorbital wrinkles (n = 22) using a ZAG peptide‐containing product. The effects of the products on skin density, elasticity, and the depth of periorbital wrinkles were evaluated using Cutometer Dual MPA580, Ultrascan, and Antera 3D CS, respectively. The effect of ZAG peptides on UVB‐treated keratinocyte cells was evaluated in vitro to understand the mechanisms underlying its effects against impaired skin barrier function, collagen degradation, and senescence. In addition, the effects of ZAG peptides on cell viability and expression of aging and skin barrier‐related genes were assessed using cell counting kit assay and quantitative reverse transcription‐polymerase chain reaction, respectively.ResultsThe patients demonstrated improved skin density, elasticity, and reduced periorbital wrinkles. Further, more than 85% patients scored the product as satisfactory regarding anti‐aging effects. Furthermore, ZAG peptides reduced SA‐β‐gal staining, downregulated the senescence‐related genes, and upregulated the skin barrier function‐related genes in UVB‐irradiated keratinocyte cells.ConclusionsOur clinical and in vitro findings showed that ZAG peptides exert anti‐aging effects and improve skin barrier functions, suggesting their promising potential as therapeutic agents to combat skin aging and improve skin health.